Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 19, 2023

SELL
$40.29 - $82.51 $134,165 - $274,758
-3,330 Reduced 31.7%
7,175 $298,000
Q1 2023

May 12, 2023

SELL
$56.44 - $118.81 $6,490 - $13,663
-115 Reduced 1.08%
10,505 $632,000
Q4 2022

Feb 10, 2023

SELL
$63.98 - $85.37 $184,262 - $245,865
-2,880 Reduced 21.33%
10,620 $779,000
Q3 2022

Nov 03, 2022

SELL
$67.99 - $89.57 $57,655 - $75,955
-848 Reduced 5.91%
13,500 $1.03 Million
Q2 2022

Aug 09, 2022

SELL
$56.6 - $89.9 $278,755 - $442,757
-4,925 Reduced 25.55%
14,348 $997,000
Q1 2022

May 09, 2022

BUY
$60.15 - $84.52 $85,052 - $119,511
1,414 Added 7.92%
19,273 $1.6 Million
Q4 2021

Feb 10, 2022

BUY
$75.08 - $121.99 $213,527 - $346,939
2,844 Added 18.94%
17,859 $1.34 Million
Q3 2021

Nov 09, 2021

BUY
$116.17 - $194.55 $414,029 - $693,376
3,564 Added 31.12%
15,015 $1.74 Million
Q2 2021

Aug 05, 2021

BUY
$130.4 - $225.58 $221,028 - $382,358
1,695 Added 17.37%
11,451 $2.54 Million
Q1 2021

May 11, 2021

BUY
$124.11 - $190.17 $219,302 - $336,030
1,767 Added 22.12%
9,756 $1.29 Million
Q4 2020

Feb 11, 2021

BUY
$112.16 - $174.14 $352,182 - $546,799
3,140 Added 64.76%
7,989 $1.38 Million
Q3 2020

Nov 02, 2020

BUY
$58.05 - $111.31 $281,484 - $539,742
4,849 New
4,849 $540,000
Q4 2018

Mar 04, 2019

SELL
$28.72 - $52.63 $214,710 - $393,461
-7,476 Closed
0 $0
Q3 2018

Nov 09, 2018

SELL
$32.0 - $52.4 $169,184 - $277,038
-5,287 Reduced 41.42%
7,476 $392,000
Q2 2018

Aug 06, 2018

BUY
$19.85 - $32.0 $56,473 - $91,040
2,845 Added 28.69%
12,763 $399,000
Q1 2018

May 08, 2018

SELL
$19.3 - $23.65 $104,779 - $128,395
-5,429 Reduced 35.37%
9,918 $216,000
Q4 2017

Feb 06, 2018

BUY
$16.3 - $21.9 $250,156 - $336,099
15,347
15,347 $310,000

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $1.79B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Teacher Retirement System Of Texas Portfolio

Follow Teacher Retirement System Of Texas and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Teacher Retirement System Of Texas, based on Form 13F filings with the SEC.

News

Stay updated on Teacher Retirement System Of Texas with notifications on news.